(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



117 MAR 2005 A MATER STOREGE DE CRANTO DE PERCENTACION ACUAL ES EN ACUAL ES EN ACUAL ACUAL ACUAL ACUAL COLOCON ACUAL ACUAL

(43) International Publication Date 1 April 2004 (01.04.2004)

PCT

(10) International Publication Number WO 2004/027384 A2

- (51) International Patent Classification7:
- **G01N**
- (21) International Application Number:

PCT/US2003/029418

(22) International Filing Date:

17 September 2003 (17.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/411,266

17 September 2002 (17.09.2002)

- (71) Applicant (for all designated States except US): PERKINELMER LIFE SCIENCES, INC. [US/US]; 549 Albany Street, Boston, MA 02118 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): JOSEPH, Richard, Abraham [US/US]; 50 Brad Road, Stoughton, MA 02072 (US). DIMEO, James, Joseph [US/US]; 442 Central Avenue, Needham, MA 02494 (US).
- (74) Agents: GOLDSTEIN, Avery, N. et al.; Gifford, Krass, Groh, Sprinkle, Anderson & Citkowski, P.C., 280 N. Old Woodward Ave., Ste 400, Birmingham, MI 48009 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCI Gazette.

(54) Title: REAL-TIME DETECTION OF NUCLEIC ACID REACTIONS


(57) Abstract: A process is provided for using oligonucleotide to which a detectable moiety is attached post-synthesis. A metalcontaining fluorescent compound affords real-time detection of nucleic acid elongation, amplification, or hybridization. The process is especially advantageous since a detectable moiety is readily attached to an existing oligonucleotide at an internal nucleotide, rather than being limited to attachment at a 3' or 5' terminus.

10

15

20

25



REAL-TIME DETECTION OF NUCLEIC ACID REACTIONS

RELATED APPLICATION

This application claims priority of United States Provisional Patent Application Serial No. 60/411,266 filed September 17, 2002, which is incorporated herein by reference.

FIELD OF THE INVENTION

This invention relates to methods of detection of nucleic acids. In particular, the invention relates to methods of real-time fluorescence-based detection of changes in quantity, length and strandedness of a nucleic acid polymer.

BACKGROUND OF THE INVENTION

Rapid detection and quantitation of nucleic acids is becoming increasingly important in basic research as well as in applied sciences. For example, many hospitals use polymerase chain reaction (PCR) to determine the identity of a pathogenic organism infecting a patient. Nucleic acid amplification techniques are also commonly used to assay environmental air and water samples suspected of contamination. Further, PCR is a key aspect of many forensic investigations. In each of these examples, it is important to obtain results as quickly and accurately as possible.

Various techniques have been developed to amplify nucleic acids including polymerase chain reaction, isothermal amplification, strand displacement amplification and ligase chain reaction. Detection and quantitation of amplified nucleic acids are currently limited by techniques that are time consuming and lacking in sensitivity. For instance, an amplification reaction may be subjected to gel electrophoresis followed by staining to visualize an approximate size and quantity of nucleic acid product. Gel detection often requires hours of processing before results are obtained.

10

15

20

25

30



Prior art methods of attaching a detectable moiety to an oligonucleotide include enzymatic incorporation of labeled nucleotides into a nucleic acid sequence, resulting in an oligonucleotide labeled at a terminus or in the internal portion of the molecule. Enzymatic incorporation techniques are inconvenient for labeling of internal nucleotides since the labeling must be performed during oligonucleotide synthesis. This precludes convenient storage of oligonucleotide stocks and on-demand labeling and use. End labeling techniques are also commonly used to incorporate a nucleotide attached to a detectable moiety and for direct bonding of a detectable label. However, many of these methods have the drawback that nucleotides must be derivatized in order to covalently bond the detectable label. Nucleotide derivatization and bonding of the label can interfere with oligonucleotide properties including ability to hybridize with specificity equal to an unlabeled oligonucleotide. Alternative methods allow bonding of a detectable moiety to an oligonucleotide at an internal nucleotide, but generally the choice of the nucleotide to which the linker is attached is limited. Further, steric hindrance is a common problem where bulky labels are attached, causing hybridization anomalies.

Thus, there exists a need for a method of detecting a nucleic acid of interest quickly and easily. Post-synthetic attachment of a detectable moiety to a nucleic acid would facilitate rapid detection.

SUMMARY OF THE INVENTION

A process for detecting an oligonucleotide elongation involves the combination of a detectable moiety with an oligonucleotide through a non-covalent association. The resulting labeled oligonucleotide is added to an oligonucleotide elongation mixture in an elongation reaction thereafter initiated. Assaying for the labeled oligonucleotide for incorporation as part of the oligonucleotide elongation process affords the desired information. A fluorescent compound is considered a preferred detectable moiety.

Measurement of a fluorescence parameter in the oligonucleotide elongation reaction mixture at a first time point yields a test measurement. The

10

15

20

25



comparison of the test measurement with a reference measurement affords oligonucleotide elongation detection.

A process for detecting oligonucleotide elongation includes providing oligonucleotide elongation reaction mixture containing an oligonucleotide labeled with a metal-containing fluorescent compound. Measurement of a fluorescence parameter associated with the metal-containing fluorescent compound in the reaction mixture at a first time point yields a test measurement. Comparison of the test measurement with a reference measurement affords oligonucleotide elongation detection. A platinum-containing fluorescent compound is particularly well suited to serve as the metal-containing fluorescent compound.

A process for detecting formation of oligonucleotide hybrid includes providing a hybridization reaction mixture containing an oligonucleotide labeled with a metal-containing fluorescent compound. Measuring a fluorescence parameter associated with the metal-containing fluorescent compound at a first time point yields a test measurement associated with the reaction mixture. Comparison of the test measurement with a reference measurement affords oligonucleotide hybridization detection.

A commercial package includes a metal-containing fluorescent compound reaction mixture component along with instructions for use thereof to detect changes in an oligonucleotide indicative of elongation of hybridization. The use of a detectable moiety attached post-synthesis to an oligonucleotide for real-time detection of changes in nucleic acid elongation or hybridization is also provided.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides methods for detecting and quantifying nucleic acids that overcome the limitations of prior technologies. In particular, the present invention provides methods of using a labeled nucleic acid oligonucleotide for real-time detection of changes in the oligonucleotide indicative of elongation and/or hybridization. The invention further provides methods for quantification of a nucleic acid of interest.


10

15

20

25

30



A method of the present invention for detecting oligonucleotide changes and/or quantitating a nucleic acid target includes the step of providing an oligonucleotide. Characteristics of a provided oligonucleotide sequence such as length, sequence and base composition depend on the type of reaction to be performed and the target nucleic acid to be detected. Typical reactions performed include an elongation reaction and a hybridization. Elongation reactions include, for example, a reverse transcription reaction and a polymerase chain reaction. It is appreciated that elongation reactions may include both a hybridization step and an elongation step and these may be detected separately according to an inventive method. A hybridization reaction may include formation of a DNA:DNA, DNA:RNA or RNA:RNA complex between a provided labeled oligonucleotide and a target nucleic acid. The target nucleic acid is any nucleic acid that a user desires to detect, for example, genomic DNA, mitochondrial DNA, total RNA, mRNA, tRNA and synthetic nucleic acids. Characteristics of an oligonucleotide suitable for these and related reactions are known in the art and are detailed in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 3rd Edition, 2001 and Dieffenbach, C.W. and Dveksler, G.S., PCR Primer: A Laboratory Manual, Cold Spring Harbor Laboratory, 1995.

An oligonucleotide to be used in an inventive method is labeled by attachment to a detectable moiety. A detectable moiety is a compound whose presence can be discovered upon application of an appropriate detection technique. For example, a detectable moiety is a fluorescent compound whose presence is discernable using techniques such as fluorimetry. Further examples of a detectable moiety include a biotin-containing compound, a compound containing an enzyme, such as horseradish peroxidase, or a radioactive compound. It is appreciated that in addition to excitation and direct detection of a fluorescent label according to the present invention, fluorescence resonance energy transfer (FRET) is operative herein with excitation of a first label moiety detected by fluorescence of a second label brought into proximity to the first label through elongation.

In order to overcome the limitations of the prior art, the present invention provides a process using an oligonucleotide in which a detectable moiety is

10

15

20

25

30



attached post-synthesis. In a preferred embodiment, an oligonucleotide is attached to a detectable moiety that includes a fluorophore. Numerous fluorophores are known in the art including fluorescein, rhodamine, Cy-3, Cy-5, and others such as those listed in Handbook of Fluorescent Probes and Research Products, 8th Edition (Molecular Probes, Eugene, OR). It has been found that a metal-containing fluorescent compound used to label an oligonucleotide is particularly useful in a process for real-time detection of nucleic acid elongation, amplification, or hybridization. These fluorescent compounds are especially advantageous for use in an inventive process since a detectable moiety is readily attached to an existing oligonucleotide at an internal nucleotide, rather than being limited to attachment at the 5' or 3' terminus. In addition, a fluorescent compound is advantageous in not appreciably interfering with nucleic acid hybridization. Thus, a method according to the present invention allows a user to perform more rapidly the process of detecting a nucleic acid. The increased speed results from oligonucleotides of interest being stored until needed, quickly labeled, and used in a reaction, in which the product is detected by real-time changes in a fluorescent signal.

A particularly preferred label for an oligonucleotide used in an inventive method is a metal-containing fluorescent compound. Metals included in such compounds are the platinum group metals including platinum, palladium, rhodium, ruthenium, osmium, and iridium. For example, ULYSIS labels, such as ULYSIS Alexa Fluor 546 (Molecular Probes), are platinum-containing fluorescent compounds that are suitable labels for an oligonucleotide to be used in a method of the present invention, as detailed in the examples below. Further examples of suitable labels include those available commercially as Cy-Dye ULS fluorescent nucleic acid labels (Amersham) and those described in U.S. Patent No. 6,338,943. Details of attaching a fluorescently labeled metal-containing compound to an oligonucleotide are found in Example 1 and in literature available from Molecular Probes including the Handbook of Fluorescent Probes and Research Products, 8th Edition (Molecular Probes, Eugene, OR).

In a method according to the present invention, the oligonucleotide is optionally labeled through a bond that is other than a covalent bond where each of

10

15

20

25

30



the two bond atoms donates at least one electron to the bond, hereafter referred to as a "dual contribution covalent bond." Binding through a bond other than a dual contribution covalent bond includes, for instance, formation of an ionic bond, hydrogen bond, Van der Waals interaction, and an organometallic coordinate covalent bond, between a compound including a detectable moiety and the oligonucleotide. An example of non-covalent binding that occurs as a combination of the above includes biological recognition interactions such as antibody/antigen binding.

Following oligonucleotide labeling, unlabeled oligonucleotide is preferably separated away from an unreacted detectable moiety. Separation is by a method known in the art such as use of a filtration column containing Sephadex or an art recognized equivalent as in Example 1. Suitable purification columns include those commercially available as ProbeQuant G50 Micro Column (Amersham Pharmacia Biotech, Piscataway, NJ) and Label It Spin columns (PanVera).

In order to proceed with detection using an inventive method, a reaction mixture, such as an elongation, amplification or hybridization mixture, is prepared according to procedures known in the art. For instance, an elongation or amplification reaction may be a polymerase chain reaction, ligase chain reaction and, generally, reactions containing a nucleic acid polymerase. A typical PCR reaction mixture includes a first primer, which is fluorescently labeled as described above, a second primer that is optionally labeled, a nucleotide mix, a nucleic acid to be amplified and an enzyme. PCR reaction mixtures are known in the art and general guidelines regarding composition are found in Dieffenbach, C.W. and Dveksler, G.S., PCR Primer: A Laboratory Manual, Cold Spring Harbor Laboratory, 1995. A specific example is detailed in Example 2. A reaction mixture may be a hybridization mixture which typically includes a hybridization buffer, a nucleic acid target and a fluorescently labeled oligonucleotide probe. General guidelines regarding hybridization reaction mixtures are found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, 3rd Edition, 2001.

10

15

20

25

30

Once a reaction mixture is assembled, an optional initial measurement of an oligonucleotide labeled with a detectable moiety in the reaction mixture is made. The measurement technique used depends on the detectable moiety used. In a preferred embodiment, a detectable moiety is a fluorescent compound, and measurement of a fluorescence parameter is made. Fluorescence parameters include, for example, fluorescence polarization and fluorescence intensity.

Fluorescence polarization is a particularly preferred mode of detection of nucleic acid changes according to the present invention. polarization measurements are used to detect differences in rotation of fluorescent molecules. Since a larger fluorescent molecule rotates more slowly than a smaller fluorescent molecule, changes in fluorescence polarization in a reaction including a fluorescently labeled oligonucleotide are indicative of changes in size of the oligonucleotide or its binding to another molecule. For example, fluorescence polarization changes are indicative of oligonucleotide binding to a polypeptide, hybridization with another nucleic acid sequence and elongation of the oligonucleotide. Fluorescence polarization measurements are made by directing polarized exciting light into a sample and measuring the polarized light emitted from the excited fluorophore. The technique is independent of fluorescence intensity as long as the signal is above the detection threshold of the detection Various instruments are available commercially for equipment used. measurement of fluorescence polarization. For example, a Victor2 V device (PerkinElmer Life Sciences, Boston, MA) is used to measure fluorescence polarization in an inventive method as described Example 2. Further general characteristics of methods and tools for fluorescence measurement are known in the art and are described in J.R. Lakowicz, Principles of Fluorescence Spectroscopy, 1999, 2nd Edition. In addition, information relating to fluorescence polarization and nucleic acid detection is found in U.S. Patent No. 6,022,686.

Changes in fluorescence intensity measurements in a nucleic acid amplification mixture correlate with changes in nucleic acid concentration. Fluorescence intensity measurements are made with any standard fluorimeter such

10

15

20

25

30



as the Victor2 V device commercially available from PerkinElmer Life Sciences, Boston.

It is appreciated that multiple assays can be run in a single tube using oligonucleotides labeled with fluorophores having different excitation and/or emission spectra.

In methods to detect changes in a fluorescently labeled oligonucleotide, comparisons are made between a test measurement of a fluorescence parameter in the oligonucleotide-containing reaction mixture at a first time point and a reference. A reference may be a second measurement of a fluorescence parameter in the oligonucleotide reaction mixture at a second time point. The second time point may be before initiation of the reaction, i.e. to measure a basal level of a fluorescence parameter and to normalize for any background fluorescence. For example, in a PCR reaction, a reference measurement may be taken when an oligonucleotide is hybridized to target nucleic acid but before addition or activation of a polymerase.

Where a reference measurement is made in the reaction mixture prior to the reaction taking place, a subsequent step is reaction initiation. The type of initiation step depends on the type of reaction and the appropriate reaction initiation will be recognized by one skilled in the art. For example, where the reaction is a polymerase chain reaction, the reaction may be initiated by addition or activation of an enzyme such as Taq polymerase. A hybridization reaction is typically initiated by heating to dissociate double-stranded nucleic acid followed by bringing the mixture to incubation temperature.

It is apparent that more than two fluorescence measurements may be made and compared. In a method to detect an oligonucleotide elongation, such as occurs in a polymerase chain reaction, a first reference measurement may be made in a reaction mixture containing labeled oligonucleotide before the reaction is heated and cooled to dissociate any double-stranded nucleic acids present and hybridize the oligonucleotide to a target. Subsequently, a second reference measurement may be made once the oligonucleotide hybridization has taken


10

15

20

25

30



place. Then, the polymerase chain reaction is initiated, for instance by addition of a suitable polymerase and a desired number of test measurements are made.

Alternatively, the first and second time points are after initiation of the elongation reaction.

Following reaction initiation, a test measurement of the reaction mixture is made. The reference and test measurements are then compared, resulting in an indication of changes in quantity, length and strandedness of a nucleic acid polymer such that an elongation, amplification or hybridization reaction is detected.

In an alternative embodiment, a reference is a measurement of a fluorescence parameter in a second oligonucleotide reaction mixture. For example, fluorescence measurements in a reaction mixture containing an unknown amount or type of nucleic acid sequence to be amplified may be compared to measurements in a reference reaction mixture in order to normalize for background or for quantitation. In an exemplary method, assessment of quantity of nucleic acid target is made by comparison to standard reactions containing known amounts of nucleic acid target. Standard reactions are preferably run in parallel with reactions containing an unknown amount of target. A standard curve relating amount of nucleic acid target and fluorescent signal is then generated and the amount of target nucleic acid present in the unknown sample is determined by comparison to the standard curve. Alternatively, a standard curve may be generated by using an internal standard as a reference. An internal standard may be a known amount of a nucleic acid added to a reaction mixture containing an unknown amount of a nucleic acid. The test and reference measurements may be made in parallel in the same reaction mixture.

A commercial package or kit is provided for detecting changes in an oligonucleotide indicative of oligonucleotide extension or hybridization. The kit includes reaction mixture components selected from, for example, nucleotides, a reaction buffer, a polymerase, a column for purification of a labeled oligonucleotide, nucleic acid purification reagents, standards and instructions for use of the components to detect changes in an oligonucleotide indicative of


10

15

20

25

30



elongation or hybridization. In a preferred embodiment, a kit includes reaction mixture components and instructions on using an oligonucleotide labeled with a metal-containing fluorescent compound to detect changes in an oligonucleotide by detection of a fluorescence parameter.

Examples

Example 1

Labeling of Primer

To 5 micrograms of a tubulin forward primer is added 1 microliter ULYSIS TM Alexa Fluor 546 reagent (Molecular Probes, Eugene, OR), brought up in 100 microliters of 50% dimethyl formamide, and 5 millimolar Tris-HCl pH 7.6 to a final volume of 20 microliters. The solution is heated at 85°C for 30 minutes, and the volume is adjusted to 77 microliters with Tris buffer. The labeled primer is purified on a ProbeQuant G50 Micro Column (Amersham Pharmacia Biotech, Piscataway, NJ). Final concentration is 10 micromolar.

Example 2

Polymerase Chain Reaction and Detection

The PCR mixture is prepared as follows:


To 25 microliters of PCR Supermix with Platinum Taq (Invitrogen Life Technologies, Carlsbad, CA) is added 1 microliter of labeled primer from Example 1, 1 microliter of a 10 micromolar solution of unlabeled tubulin reverse primer and 1 microliter of a 5 picogram/microliter tubulin DNA solution. The solution is thermalcycled on an MJ Research PTC-100 thermal controller (MJ Research, Watertown, MA) at 95°C for 3 minutes, and then 40 cycles of 95°C for 20 seconds and 55°C for 20 seconds, and then held at 4°C.

Twenty microliters of the PCR products and a control mixture where no PCR cycling is done are removed and placed into a well of an MJ 386 plate. Fluorescence polarization is measured in a Victor2 V (PerkinElmer Life Sciences, Boston, MA).

The control, or reference, mixture fluorescence polarization is 258 mP and the 40 cycle mixture fluorescence is 301 mP, for a 43 mP increase. This change in

10

15



fluorescence polarization demonstrates that fluorescence polarization is a measure of primer elongation.

Aspects of fluorescence measurements in detection of nucleic acids are described in U.S. Patent No. 6,022,686.


Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will readily appreciate that the present invention is well adapted to obtain the ends and advantages mentioned, as well as those inherent therein. The present methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.



CLAIMS


1	1.	A process of detecting an oligonucleotide elongation, the process	
2	comprising the	he steps of:	
3	(a)	providing an oligonucleotide;	
4	(b)	combining a detectable moiety and the oligonucleotide to form a	
5		labeled oligonucleotide, the labeled oligonucleotide characterized	
6		by an association independent of a dual contribution covalent bond	
7		between the detectable moiety and the oligonucleotide;	
8	(c)	adding the labeled oligonucleotide to an oligonucleotide elongation	
9		mixture;	
l0	(d)	initiating an elongation reaction in the oligonucleotide elongation	
11		mixture; and	
12	(e)	assaying for the labeled oligonucleotide in the oligonucleotide	
13		elongation mixture to detect the oligonucleotide elongation.	
1	2.	The process of claim 1 wherein the non-covalent association is	
2	selected from the group consisting of: an ionic bond, a hydrogen bond, a Van der		
3	Waals interac	ction and an organometallic coordinate covalent bond.	
1	3.	The process of claim 1 wherein the detectable moiety comprises a	
2	fluorophore.		
1	4.	The process of claim 1 wherein the detectable moiety comprises a	
2	metal-containing fluorescent compound.		
1	5.	The process of claim 4 wherein the metal-containing fluorescent	
2	compound co	omprises platinum.	
1	6.	The process of claim 4 wherein the metal-containing fluorescent	
2	compound co	omprises a metal selected from the group consisting of: palladium,	
3	-	nenium, osmium, and iridium.	




1	7.	The process of claim 1 wherein the elongation reaction is a			
2	polymerase chain reaction.				
1	0	The manager of claims I subscribe the claim of the claims			
1	8.	The process of claim 1 wherein the elongation reaction is a reverse			
2	transcription	reaction.			
1	9.	The process of claim 1 wherein the elongation reaction is a primer			
2	extension rea	action.			
1	10.	The process of claim 1 wherein the elongation reaction is a ligase			
2	chain reactio	n.			
1	11.	The process of claim 1 wherein the process further comprises the			
2	step of purify	ring the labeled oligonucleotide.			
1	12.	The process of claim 1 wherein the step of assaying the labeled			
2	oligonucleoti	de comprises a measurement of fluorescence polarization.			
1	10				
1	13.	The process of claim 1 wherein the step of assaying the labeled			
2	oligonucleoti	de comprises a measurement of fluorescence intensity.			
1	14.	The process of claim 1 wherein the step of assaying the labeled			
2		de comprises a measurement of fluorescence resonance energy			
3	transfer.	de comprises a measurement of fluorescence resonance energy			
J	uansici.				
1	15.	A process of detecting an oligonucleotide elongation, the process			
2	comprising th				
3	(a)	providing an oligonucleotide elongation reaction mixture			
4	• •	comprising an oligonucleotide labeled with a fluorescent			
5		compound by an association independent of a dual contribution			
6		covalent bond;			




7	(b)	measuring a fluorescence parameter in the oligonucleotide
8		elongation reaction mixture at a first time point to obtain a test
9		measurement; and
10	(c)	comparing the test measurement with a reference measurement to
11		detect the oligonucleotide elongation.
		·
1	16.	The process of claim 15 wherein the reference is a second
2	measurement	of a fluorescence parameter in the oligonucleotide reaction mixture
3	at a second ti	me point.
1	17.	The process of claim 16 wherein the second time point is before
2	initiation of t	he elongation reaction.
1	18.	The process of claim 16 wherein the first and second time points
2	are after initia	ation of the elongation reaction.
1	19.	The process of claim 15 wherein the reference is a measurement of
2	a fluorescenc	e parameter in a second oligonucleotide extension reaction mixture.
1	20.	The process of claim 15 wherein the non-covalent association is
. 2	selected from	the group consisting of: an ionic bond, a hydrogen bond, a Van der
3	Waals interac	ction and an organometallic coordinate covalent bond.
1	21.	The process of claim 15 wherein the fluorescent compound is a
2	metal-contair	ning fluorescent compound.
1	22.	The process of claim 21 wherein the metal-containing fluorescent
2	compound co	omprises platinum.
-	03	The process of claim 21 wherein the metal containing fluorescent
1	23.	The process of claim 21 wherein the metal-containing fluorescent
2	-	omprises a metal selected from the group consisting of: palladium, nenium, osmium, and iridium.
3	rnoaium, ruti	icinum, osimum, and maiam.



1	24.	The process of claim 15 wherein the elongation reaction is a				
2	polymerase c	polymerase chain reaction.				
1	25.	The process of claim 15 wherein the elongation reaction is a				
2	reverse transc	cription reaction.				
1	26.	The process of claim 15 wherein the elongation reaction is a primer				
2	extension rea	extension reaction.				
1	27.	The process of claim 15 wherein the elongation reaction is a ligase				
2	chain reaction	•				
1	28.	The process of claim 15 wherein the fluorescence parameter is				
2	selected from	the group consisting of: fluorescence polarization and fluorescence				
3	intensity and fluorescence resonance energy transfer.					
1	29.	A process of detecting an oligonucleotide elongation, the process				
2	comprising th	ne steps of:				
3	(a)	providing an oligonucleotide elongation reaction mixture				
4		comprising an oligonucleotide labeled with a metal-containing				
5		fluorescent compound;				
6	(b)	measuring a fluorescence parameter associated with the metal-				
7		containing fluorescent compound in the oligonucleotide elongation				
8		reaction mixture at a first time point to obtain a test measurement;				
9		and				
10	(c)	comparing the test measurement with a reference measurement to				
11		detect the oligonucleotide elongation.				
	•					
1	30.	The process of claim 29 wherein the metal-containing fluorescent				
2	compound co	omprises platinum.				



1	31.	The process of claim 29 wherein the metal-containing fluorescent		
2	forms a coordinate covalent bond to label the oligonucleotide.			
1	32.	The process of claim 29 wherein the metal-containing fluorescent		
2		omprises a metal selected from the group consisting of: palladium,		
3	_	nenium, osmium, and iridium.		
		,		
1	33.	The process of claim 29 wherein the elongation reaction mixture is		
2	a polymerase	chain reaction mixture.		
1	34.	The process of claim 29 wherein the fluorescence parameter is		
2		the group consisting of: fluorescence polarization, fluorescence		
3	intensity and fluorescence resonance energy transfer.			
	•			
1	35.	The process of claim 29 wherein the reference is a second		
2	measurement	of a fluorescence parameter in the oligonucleotide reaction mixture		
3	at a second ti	me point.		
_	2.5			
1	36.	The process of claim 35 wherein the second time point is before		
2	initiation of t	he elongation reaction.		
1	37.	The process of claim 35 wherein the first and second time points		
2	are after initi	ation of the elongation reaction.		
1	38.	The process of claim 29 wherein the reference is a measurement of		
2	a fluorescenc	e parameter in a second oligonucleotide extension reaction mixture.		
1	39.	A process of detecting formation of an oligonucleotide hybrid, the		
2	process comp	orising the steps of:		
3	(a)	providing a hybridization reaction mixture comprising an		
4		oligonucleotide labeled with a metal-containing fluorescent		
5		compound;		



6	(b)	measuring a fluorescence parameter associated with the metal-		
7		containing fluorescent compound in the hybridization reaction		
8		mixture at a first time point to obtain a test measurement; and		
9	(c)	comparing the test measurement with a reference measurement to		
10		detect the oligonucleotide hybridization.		
		·		
1	40.	The process of claim 39 wherein the metal-containing fluorescent		
2	compound co	omprises platinum.		
	1			
1	41.	The process of claim 39 wherein the metal-containing fluorescent		
2	forms a coord	dinate covalent bond to label the oligonucleotide.		
1	42.	The process of claim 39 wherein the metal-containing fluorescent		
_		-		
2	-	omprises a metal selected from the group consisting of: palladium,		
3	rnodium, rutr	nenium, osmium, and iridium.		
1	43.	The process of claim 39 wherein the reference is a second		
2		of a fluorescence parameter in the oligonucleotide reaction mixture		
3	at a second ti			
,	ar a boothe a	me pomi.		
1	44.	The process of claim 43 wherein the second time point is before		
2	initiation of the	he elongation reaction.		
1	45.	The process of claim 43 wherein the first and second time points		
2	are after initia	are after initiation of the elongation reaction.		
1	46.	The process of claim 39 wherein the reference is a measurement of		
2	a fluorescence	e parameter in a second oligonucleotide extension reaction mixture.		
	•			
1	47.	The process of claim 35 wherein the fluorescence parameter is		
2	selected from	the group consisting of: fluorescence polarization, fluorescence		
3	intensity and	fluorescence resonance energy transfer.		
		•		

1	48.	A process for detection of changes in a nucleic acid essentially as
2	described her	rein in any of the examples.
1	49.	A process for nucleic acid quantification essentially as described
2	herein in any	of the examples.
1	50.	A commercial package comprising a metal-containing fluorescent
2	compound re	action mixture component along with instructions for use thereof to
3	detect change	es in an oligonucleotide indicative of elongation or hybridization.
1	51.	The use of a detectable moiety attached post-synthesis to an
2	oligonucleoti	de for real-time detection of changes in nucleic acid elongation,
3	amplification	or hybridization.
1	52.	The use of claim 51 wherein the detectable moiety is a fluorophore.
1	53.	The use of claim 52 wherein the fluorophore is a metal-containing
2	fluorescent c	ompound.
1	54.	The use of claim 53 wherein the metal-containing fluorescent
2	compound co	ontains platinum.

(19) World Intellectual Property Organization

International Bureau

(43) International Publication Date

1 April 2004 (01.04.2004)



PCT

(10) International Publication Number WO 2004/027384 A3

(51) International Patent Classification7:

C12Q 1/68

(21) International Application Number:

PCT/US2003/029418

(22) International Filing Date:

17 September 2003 (17.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/411,266

17 September 2002 (17.09.2002)

(71) Applicant (for all designated States except US): PERKINELMER LIFE SCIENCES, INC. [US/US]; 549 Albany Street, Boston, MA 02118 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JOSEPH, Richard, Abraham [US/US]; 50 Brad Road, Stoughton, MA 02072 (US). DIMEO, James, Joseph | US/US|; 442 Central Avenue, Needham, MA 02494 (US).

(74) Agents: GOLDSTEIN, Avery, N. et al.; Gifford, Krass, Groh, Sprinkle, Anderson & Citkowski, P.C., 280 N. Old Woodward Avc., Stc 400, Birmingham, MI 48009 (US). (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 11 November 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: REAL-TIME DETECTION OF NUCLEIC ACID REACTIONS

(57) Abstract: A process is provided for using oligonucleotide to which a detectable moiety is attached post-synthesis. A metal-containing fluorescent compound affords real-time detection of nucleic acid elongation, amplification, or hybridization. The process is especially advantageous since a detectable moiety is readily attached to an existing oligonucleotide at an internal nucleotide, rather than being limited to attachment at a 3' or 5' terminus.





Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/29418

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12Q 1/68					
US CL	: 435/6	and all dealfantes 175			
B. FIEL	Distributional Patent Classification (IPC) or to both DS SEARCHED	DEMONIAL CLASSIFICATION and IPC			
Minimum do	cumentation searched (classification system followed	by classification symbols)			
	35/6, 91.1, 91.2, 183; 536/23.1, 24.31, 24.33		*		
Documentati	on searched other than minimum documentation to the	e extent that such documents are included	l in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EAST (USPAT, USPGP, EPO, JPO, DERWENT); STN (CA, BIOSIS, MEDLINE)					
	UMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where a		Relevant to claim No.		
Y	US 5,541,067 A (PERLIN) 30 July 1996 (30.07.19	96), see column 4, last paragraph.	1-47, 50		
Y	US 5,599,674 A (PENA et al.) 04 February 1997 (04.02.1997), see column 10.	1-47, 50		
Y	US 5,639,611 A (WALLACE et al.) 17 June 1997	(17.06.1997), column 5.	1-47, 50		
Υ -	US 6.090,933 A (KAYYEM et al.) 18 July 2000 (1	8.07.2000), columns 44-45.	1-47, 50		
Y	US 2002/0006643 A1 (KAYYEM et al.) 17 January	y 2002 (17.01.2002), page 42.	1-47, 50		
Y	US 2002/0064788 A1 (MONFORTE) 30 May 2002	1-47, 50			
Y	TABOR et al. Proceedings of the National Academ	ny of Sciences, July 1995, USA, Vol.	1-47, 50		
92, pages 6339-6343. Y KORCH et al. Nucleic Acids Research, 1999, Vol. 27, No. 5, pages 1405-1407.			1-47, 50		
Y, P	US 2002/014230 A1 (ANDERSON et al.) 03 Octo	ober 2002 (03.10.2002), column 8.	1-47, 50		
	dogramon and listed in the service of Section 2	5			
	documents are listed in the continuation of Box C.	See patent family annex.			
	pecial extegories of cited documents:	priority date and not in conflict with	the application but cited to		
	t defining the general state of the art which is not considered to ticular relevance	understand the principle or theory un			
"B" carlier ap	plication or patent published on or after the international filling	"X" document of particular relevance; the considered novel or cannot be considered step when the document is taken along	ered to involve an inventive		
"L" document to establi (2s specif	which may throw doubts on priority claim(s) or which is cited sh the publication date of another citation or other special reason led)	"Y" document of particular relevance; the considered to involve an inventive ste combined with one or more other such	p when the document is a documents, such		
"O" document	referring to an oral disclosure, use, exhibition or other means	combination being obvious to a person "&" document member of the same patent			
nriority (published prior to the international filing date but later than the				
Date of the a	ctual completion of the international search	Date of mailing of the international sear	ch report		
	2004 (15.02.2004)		~ ~~~~		
	ailing address of the ISA/US	Authorized officer	1200 l		
	1 Stop PCT, Attn: ISA/US nmissioner for Patents	Authorized officer Bradley L. Sisson C. JUKUL	e Toux		
P.O	. Box 1450	Telephone No. 703-308-1234	_		
	xandria, Virginia 22313-1450 b. (703) 305-3230	тегерионе 140. 703-308-1234	100		



	PCT/US03/29418
INTERNATIONAL SEARCH REPORT	

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category • 1-47, 50 US 6,472,160 B2 (SARUTA et al.) 29 October 2002 (29.10.2002), column 10. A, P

Form PCT/ISA/210 (second sheet) (July 1998)



Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)					
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. Claim Nos.: 51-54 because they relate to subject matter not required to be searched by this Authority, namely: Claims 51-54 were not searched as they are a form of use claim.					
2. Claim Nos.: 48 and 49 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Please See Continuation Sheet					
3. Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).					
Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)					
This International Searching Authority found multiple inventions in this international application, as follows:					
 As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 					
A. No required additional search fees were timely paid by the applicant. Consequently, this international search report					
is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:					
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.					

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)





n t	Continuation of Eox I Reason 2: Claims 48 and 49 are sufficiently indefinite as to make searching impossible. Said claims 48 and 49 do not recite any method steps for identify which examples found within the written description are to be encompassed by the claims ro modified, or to what extent hey are to be modified.	
(Claims 51-54 are unsearchable as they constitute "use claims."	
		ĺ
١		
١		
	• •	
	·	
		١

Form PCT/ISA/210 (second sheet) (July 1998)